Visual Outcomes and Patient Satisfactory After PanOptix Implantation in Hyperopic Cataract Patients
NCT ID: NCT05716269
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
44 participants
OBSERVATIONAL
2023-02-28
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Visual Outcomes of Functional Intraocular Lenses in Cataracts
NCT06092164
Prospective Clinical Study of Unilateral or Bilateral Implantation of Intraocular Lens in Cataract Patients
NCT04265820
Toric Intraocular Lens (IOL) Implantation for Management of Cataracts
NCT05797298
Trifocal Intraocular Lens in High Myopic Patients With Different Meta-PM Grading
NCT05718076
The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction
NCT05346172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eye axis length ≤22.5mm and refraction ≥ +0.5D
* Predicted postoperative corneal astigmatism ≤0.75D
* mesopic pupil size between 3.0mm to 5.5 mm
* Preoperative angle kappa ≤ 0.5 mm
* Preoperative corneal spherical aberration \<0.5μm, high order aberration \<0.5μm
Exclusion Criteria
* Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)
* History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis
* Patients with history of ocular trauma or prior ocular surgery including refractive procedures
* Preoperative visual acuity of worse than 0.2 logMAR in any eye.
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Eye Hospital
OTHER
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Qi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Qi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022756
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.